Siro Perez

Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia.

Amgen AB conducts biotechnology research and experimental development. It focuses on the following therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation. The company was founded in 1980 and is headquartered in Solna, Sweden.

Medicines Australia is a non-profit organization which designs, develops, and implements health and industry policies for pharmaceutical industry. It builds and maintains relationships with government for fair reimbursement of medicines to ensure the continuation of a viable medicines industry, administers the Medicines Australia Code of Conduct which sets the standard for the ethical marketing and promotion of prescription medicines, and provides specialist advice to member companies. The organization is headquartered in Deakin, Australia.

OneVentures Management Pty Ltd. (OneVentures) is a venture capital firm, a susbidiary of Andover Group Pty Ltd was founded in 2006 by Dr Michelle Deaker. The firm is headquartered in Australia.

Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA.

Axial Therapeutics, Inc. provides biopharmaceuticals. It is harnessing the link between the human get microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders. The company was founded by Sarkis Mazmanian and David H. Donabedian and is headquartered in Boston, MA.

Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany.

Envisagenics, Inc. engages in developing of artificial intelligence platform for discovering drugs. The company was founded by Maria Luisa Pineda and Martin Akerman and is headquartered in New York, NY.

ProTA Therapeutics Pty Ltd. manufactures pharmaceutical products. The company was founded by Mimi Tang on September 23, 2016 and is headquartered in Melbourne, Australia.

MetabloQ Pty Ltd. develops drugs for cancer treatment. It treats triple-negative breast cancer, prostate cancer and melanoma cancer diseases. The company was founded in 2016 and is headquartered in Melbourne, Australia.

Cincera Therapeutics Pty Ltd. is a biotechnology company, which develops molecule drugs. It focuses on the discovery and development of new small molecule drugs aiming to treat difficult-to-treat inflammatory and fibrotic conditions associated with obesity and metabolic disorders, with potential applications in many other disease areas including cancer. The company was founded by Bernard Flynn and Stuart Pitson and is headquartered in Melbourne, Australia.

Oculo Therapy LLC is an American biotechnology company.

Part of Revenio Group Oyj, CERA Technologies Pty Ltd. is a world-leading eye care platform that connects ophthalmology, optometry, primary care, emergency rooms, and patients to share clinical information and enhance referrals, triage, and collaborative care. The company is based in Melbourne, Australia. The technology enhances collaboration, bridges disconnected data silos, and delivers fast, efficient patient care. The platform is designed to share clinical correspondence securely and instantly between health care professionals, addressing the known challenges in clinical communication between a collaborative care network of health care providers. The company complies with the data protection regulations of HIPAA, the GDPR, and the Australian Privacy Principles. The company was founded in 2015 by Kate Taylor, Jonathan Crowston. Kate Taylor has been the CEO since 2015. CERA Technologies was acquired by Revenio Group Oyj on April 27, 2021 for $14.42 million.

Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile.